XOMA Royalty Corp.
NASDAQ:XOMA · NASDAQ Global Market
-$0.01 today
Vol 0.13M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.5%
avg 105.7%
ROIC
4.5%
avg -47.2%
ROA
11.6%
avg -19.0%
Analysis
ROE is currently the strongest return metric at 30.5% versus its period average of 105.7%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Owen Hughes Jr. | Chief Executive Officer & Director | $1.14M | — | 51 | $191,264.00 | 1.53% |
Brad Sitko | Chief Investment Officer | $853,495.00 | — | 45 | $82,961.00 | 0.66% |
Juliane Snowden | Head of Investor Relations | — | — | — | — | — |
Jeffrey Trigilio | Chief Financial Officer | — | — | 42 | $126,924.00 | 1.01% |
Maricel Perea Montano | Chief Legal Officer & Corporate Secretary | — | — | — | $41,793.00 | 0.33% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.56M
Sells
3
$155,820.10
Net Sentiment
+$2.40M
Net buying
Most Active
BURNS THOMAS M.
3 transactions
Analysis
Insiders reported 2 buys worth $2.56M and 3 sells worth $155,820.10 over the last 12 months. That adds up to net buying of $2.40M. BURNS THOMAS M. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +18.0% | +2.4% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.0% over three years. Forward estimates point to Revenue at +2.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Who manages XOMA?
XOMA Royalty Corp. (XOMA) lists 5 active executives. The top listed executive is Brad Sitko, Chief Investment Officer.
Are XOMA insiders buying or selling?
Recent insider activity shows net buying of $1.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.